News Features Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate Michael O'Riordan November 27, 2017
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List Michael O'Riordan November 12, 2017
News Daily News Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration Yael L. Maxwell October 23, 2017
News Daily News Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI Yael L. Maxwell October 03, 2017
News Daily News Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds Yael L. Maxwell September 12, 2017
News Conference News ESC 2017 ESC Updates Guidelines for Treating STEMI Patients Michael O'Riordan August 27, 2017
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Daily News Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests Michael O'Riordan August 14, 2017
News Daily News Lipid-Rich Plaque in Nonculprit Regions of the Target Vessel Predicts Future MACE Risk Caitlin E. Cox May 15, 2017
News Conference News ACC 2017 DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions Yael L. Maxwell March 19, 2017
News Daily News Updated AUC for Stable Ischemic Heart Disease Seek to Match ‘Appropriateness’ to Current Practice Caitlin E. Cox March 10, 2017